ClinicalTrials.gg
RecruitingNCT07445516OESTUpdated Mar 4, 2026

Occlusal Equilibration vs. Sham Therapies for TMDs: Post-Trial Follow-up (OEST)

An observational study in Temporomandibular Disorders (TMD), Myalgia of Mastication Muscle and Arthralgia Syndrome, sponsored by Urbano Santana Penin. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Urbano Santana Penin · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
110
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Temporomandibular Joint Disorders with a site in Spain — 12 open to participants now, 13 under way, none of them phase 3. Temporomandibular Joint Disorders · Spain.

Started
2026
with 1 other
Observational
8 of 40
4 open now
Primary completion
2026-06
later than 6 of 12 live
Registered
39th of 40
by date

Among the 40 studies in Temporomandibular Joint Disorders with a site in Spain, this one is one of 2 that started in 2026, is one of 8 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 39th registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

12 of the 40 studies in Temporomandibular Joint Disorders with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Temporomandibular Joint Disorders with a site in Spain, or all of them as a file.
02

Study summary

Chronic temporomandibular disorders (TMDs) affect the masticatory muscles, the temporomandibular joints (TMJs), and associated structures. Except in cases of trauma, their etiology remains uncertain, debated, and multifactorial. Conservative therapies-including no active intervention-often alleviate symptoms; however, approximately 3% of the population develops persistent forms associated with substantial individual suffering and significant social and economic burden.

At the Unit of Occlusion and Prosthodontics of the University of Santiago de Compostela (USC), Physiologically Oriented Occlusal Equilibration (POOE) has been used for chronic painful TMDs since 1985. POOE aims to correct unilateral mastication patterns and to establish appropriate non-working side contacts in order to protect the temporomandibular joints from mechanical overload. Singh (Cochrane, 2024) emphasized that occlusal interventions should be evaluated with long-term follow-up of at least 3-5 years.

This is a single-blind study: the evaluator remains blinded to treatment allocation during outcome assessment. The aim of this observational study is to assess the long-term effectiveness of POOE treatments for chronic TMDs from 1985 to the present. Treatment effectiveness will be confirmed if the reduction in pain achieved with POOE is statistically significant and clinically meaningful (≥1.5/10 on a 0-10 visual analog scale) compared with sham therapy at ≥3 years post-intervention relative to baseline. Additionally, effectiveness will be supported if the proportion of individuals meeting criteria for chronic TMD ("affected") is lower in the POOE-treated group than in those receiving alternative therapies.

Read the detailed description

Chronic TMDs constitute a complex syndrome that is currently understood as comprising more than 30 distinct nosological entities. The underlying cause of their pathophysiology has not been fully elucidated. Consequently, treatments are typically empirical and applied simultaneously, including pharmacotherapy, counseling, physiotherapy, occlusal splints (perhaps the most widely used), physical modalities, and other minimally invasive procedures such as arthrocentesis or arthroscopy, extending even to total TMJ replacement. None of these interventions has demonstrated superior efficacy compared with placebo or no treatment. Globally, these patients often consult multiple specialists and undergo numerous treatment modalities, with an unpredictable prognosis.

Physiologically oriented occlusal equilibration (POOE) was shown to be more effective than placebo at 6 months post-treatment. The 2024 Cochrane review indicated that assessing the efficacy of occlusal therapies requires evaluation at least 3 to 5 years after treatment. The treatments performed at USC since 1985 for chronic TMDs represent a valuable source of long-term clinical experience that may clarify whether POOE remains effective many years after treatment (from 1985 to the present), rather than only at 6 months.

Scientific Objectives To evaluate the effect of occlusal adjustment on pain intensity in patients with chronic TMDs during long-term follow-up over several years.

To disseminate the findings-whether positive, negative, or inconclusive-in peer-reviewed scientific journals.

Methods This is an observational study, as no intervention will be applied to participants. It will be open-label or single-blind (outcome assessors will be blinded to the treatment previously received, but participants will not be). The study is cross-sectional, as it will be conducted at a single time point and in a single visit. The study will consist of diagnosing any current TMDs potentially affecting individuals who were previously treated at USC for chronic TMDs. All participating individuals are familiar with the diagnostic procedures, which include extra- and intraoral examination, dynamic recording of mandibular and condylar movements, and the tests recommended in the DC/TMD criteria.

If the participant provides authorization, clinically relevant information from their medical record regarding TMD history will be used to determine the degree of improvement or deterioration relative to the pretreatment baseline.

03

Conditions studied

  • Temporomandibular Disorders (TMD)
  • Myalgia of Mastication Muscle
  • Arthralgia Syndrome

Keywords

  • Occlusal Equilibration
  • Occlusal Adjustment
  • TemporoMandibular Disorders (TMD)
  • Chronic Orofacial Pain
  • Randomized Clinical Trial
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All individuals previously treated with occlusal equilibration therapy at the University of Santiago de Compostela for chronic TMD pain who consent to undergo a follow-up diagnostic assessment will be eligible for inclusion. The subgroup that participated in the MAP clinical trial will be analyzed separately.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous occlusal equilibration for TMD pain at the University of Santiago.
  • Be diagnosed with joint and/or muscle TMD pain according to DC/TMD.
  • Be aged 18-85 years.
  • Be completely dentate with normal or adequately restored occlusion (fixed crowns/bridges allowed).
  • Report pretreatment significant TMD pain (VAS/NRS 4-9 on a 0-10 scale).
  • Have actively sought treatment and been referred to the University/Hospital service.
  • Have undergone ≥6 months of prior conservative therapy.

Exclusion criteria

Exclusion Criteria:

  • Psychosis, major depression, substance abuse, or cognitive impairment.
  • Opioid (morphine-derivative) addiction.
  • Ongoing litigation or disability claims related to chronic pain.
  • Dental professional background.
  • Orthodontic treatment within the last 2 years.
  • Severe tooth mobility (grade 3).
  • Other pain conditions indistinguishable from or more severe than TMD pain.
  • Additionally, patients will be excluded if minimally invasive occlusal adjustment cannot achieve equilibration, defined by: 2 mm discrepancy between maximal intercuspation and centric occlusion, and/or 4 mm total interarch discrepancy (≥2 mm on one side) in defined premolar/molars reference points, measured intraorally using a Boley gauge.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
110 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes

Groups and cohorts

  • Physilogically Oriented Occlusal Equilibration (POOE) Therapy

    Occlusal equilibration to recover physiological jaw closure and alternate chewing function

  • Sham therapy

    Simulation (placebo) of occlusal equilibration therapy

06

What researchers measure

Primary outcomes

  1. Group differences in change in pain intensity at 10 years follow-up in respect pretreatment scores.

    Differences between POOE and sham terapy groups in mean change in pain intensity at 10 years folloow-up, in respect pretreatment scores using VAS scale 0(no pain) to 10 (worst possible pain) . Greater differences indicate a better outcome.

    Time frame: Pretreatment, and 10 years follow-up

  2. Group differences in the change in maximum unassisted mouth opening

    Distance between incissors during jaw opening using 0 to 60 mm TheraBite® range of motion scale™

    Time frame: pretreatment, 10 years follow-up

  3. Odds of "success" in pain reduction of POOE compared with sham therapy

    "Success" was defined as a decrease in pain scores ≥ 2 points while decreases \<2 points, as well as unmodified or increased pain scores were labeled as "failure". We also carried out an additional analysis in which we focused on strong effects of the treatment. In this additional analysis, we redefined success as a decrease in pain ≥ 4 points, and any other effect as "failure". It will be adjusted for third covariables in order to remove any confounding bias.

    Time frame: Pretreatmen, 10 years follow-up

Secondary outcomes

  1. Psychological distress (GSI from SCL-90-R test)

    SCL-90-R. Higher scores indicate greater psychological distress. The Global Severity Index (GSI) of the SCL-90-R ranges from 0 to 4. This index represents the mean score of all 90 items, each rated on a 0-4 Likert scale (0 = not at all, 4 = extremely). Thus, GSI values can vary between 0, indicating no symptoms, and 4, indicating maximum symptom severity.

    Time frame: Pretreatment, 10 years follow-up

  2. Change in condylar path angles

    Condylar path angles are meassured between the Franckfort horizontal plane and the condylar path recprdings

    Time frame: Pretreatment, 10 years follow-up

07

Study locations

2 of 2 sites recruiting
  • Universidad de Santiago de Compostela
    Santiago de Compostela, A Coruña 15782, Spain
    Recruiting
  • Urbano Santana Penín
    Santiago de Compostela, A Coruña 15782, Spain
    Enrolling by invitation
08

References and documents

Publications

  • Santana-Mora U, Lopez-Cedrun J, Mora MJ, Otero XL, Santana-Penin U. Temporomandibular disorders: the habitual chewing side syndrome. PLoS One. 2013 Apr 8;8(4):e59980. doi: 10.1371/journal.pone.0059980. Print 2013. PubMed 23593156 ↗
  • Santana-Mora U, Lopez-Cedrun J, Suarez-Quintanilla J, Varela-Centelles P, Mora MJ, Da Silva JL, Figueiredo-Costa F, Santana-Penin U. Asymmetry of dental or joint anatomy or impaired chewing function contribute to chronic temporomandibular joint disorders. Ann Anat. 2021 Nov;238:151793. doi: 10.1016/j.aanat.2021.151793. Epub 2021 Jun 26. PubMed 34186201 ↗
  • Santana-Penin U, Santana-Mora U, Lopez-Solache A, Mora MJ, Collier T, Pocock SJ, Lorenzo-Franco F, Varela-Centelles P, Lopez-Cedrun JL. Remodeling dental anatomy vs sham therapy for chronic temporomandibular disorders. A placebo-controlled randomized clinical trial. Ann Anat. 2023 Oct;250:152117. doi: 10.1016/j.aanat.2023.152117. Epub 2023 Jun 9. PubMed 37302432 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Jun 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Mar 3, 2026
StartEst.
Feb 16, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07445516
Lead sponsor
Urbano Santana Penin
Responsible party
Urbano Santana Penin (Professor Emeritus, University of Santiago de Compostela) — Sponsor-investigator
First posted
Mar 3, 2026
Start date
Feb 16, 2026 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Mar 4, 2026

Study contacts

URBANO SANTANA PENIN, Prof.
Contact
urbano.santana@usc.es
+ 34 647 344 093
Marcos Almeida Cerreda, Officer
Contact
dpd@usc.es
+34 881 811 000
José López-Cedrún, Dr.
principal investigator · Complejo Hospitalario Universitario de A Coruña

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion